 |
Aneesa M. Das, MD
Assistant Professor
201 Davis Heart and Lung Research Institute
473 West 12th Avenue
Columbus, OH 43210
Phone: (614) 247-7707
Means Hall office fax: (614) 293-6340
Schedule a Sleep Appointment
Clinical interests
Sleep Disorders
Research interests
Patient education effect on outcomes
Improving compliance with therapy
Education
Medical School: University of Virginia, School of Medicine, MD
Undergraduate: University of Michigan, School of Engineering, BSE
Training
Fellowship: Pulmonary, Critical Care and Sleep Medicine, University of North Carolina
Residency: Department of Internal Medicine, University of North Carolina
Publications
Chapters
Das, A. Arterial Blood Gases. ICU Recall 3nd Edition, LW&W 2008
Das, A. Ventilation Basics ICU Recall 3rd Edition, LW&W 2008, Baltimore
Das, A. Pulmonary Edema. ICU Recall 3rd Edition, LW&W 2008, Baltimore
Das, A. Noninvasive Mechanical Ventilation. ICU Recall 3rd Edition, LW&W 2008, Baltimore
Das, A. Respiratory System. In: ICU Recall 2nd Edition, LW&W 2005, Baltimore
Peer Reviewed Articles
1. Das AM, Sood N, Carson SS, et al. Development of a Triage Protocol for Patients Presenting with Gastrointestinal Hemorrhage. Critical Care. 12:R57, 2008.
2. Chang LH, Das AM, Carson SS et al. Utilization of bronchodilators in ventilated patients without obstructive airways disease. Respiratory Care. Feb;52(2):154-8, 2007.
3. Amar AM, Tomlinson G, Green DM, Breslow NE, de Alarcon PE. Clinical Presentation of Rhabdoid Tumors of the Kidney. Journal of Pediatric Oncology. 41(2):105-108, 2001.
4. Kraker AJ, Amar AM, Moore CW et. al. Biochemical and Cellular effects of c-Src Kinase-Selective Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors. Biochemical Pharmacology. 60:885-898, 2000.
5. Klutchko SR, Amar AM, Doherty AM et. al. 2-substituted aminopyrido[2,3-d]pyrimidin-7(8h) ones - structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. Journal of Medicinal Chemistry. 41(17):3276-3292, 1998.
6. Barvian MR, Amar AM, Showalter HD et. al. 1-oxo-3-aryl-1h-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 7(22):2903-2908, 1997.
7. Connolly CJC, Amar AM, Doherty AM et. al. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 7(18):2415-2420, 1997.
8. Hamby JM, Amar AM, Doherty AM et. al. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Journal of Medicinal Chemistry. 40(15):2296-2303, 1997.
Abstracts
1. Das AM, Sood N, Hodgin K, Chang L, Carson SS. Validation of Risk Factors for Early Complication of Gastrointestinal Hemorrhage. Proceedings of the American Thoracic Society, Volume 3, Abstracts Issue, April 2006
2. Das AM, Paradowski L. C-Antineutrophil Cytoplasmic Antibody Vasculitis in a Patient with Primary Pulmonary Hypertension on Prostacyclin and Bosentan. Chest. 128(4 suppl):459S-460S 2005.
3. Amar AM, Tomlinson G, Green DM, Breslow NE, de Alarcon PE. The Clinical Presentation of Rhabdoid Tumors of the Kidney. Society for Pediatric Research. May 1998.
4. Kraker AJ, Amar AM, Hamby J et. al. Cytotoxicity and phosphotyrosine effects of c-src kinase inhibition by substituted pyridopyrimidine tyrosine kinase inhibitors in human colon carcinoma cell lines. Proc Annu Meet Am Assoc Cancer Res. 38:A4247 1997.
5. Showalter HD, Amar AM, Lu GH et. al. Synthesis and SAR for a series of 4-substituted 1H-pyrimido(4,5-b) and 5H-pyrimido(5,4-b)indoles as EGF receptor tyrosine kinase inhibitors. Proc Annu Meet Am Assoc Cancer Res. 37:A2899 1996.
6. Kraker AJ, Amar AM, Showalter HD et. al. Effects of c-src specific tyrosine kinase inhibitors on cellular phosphorylation, signaling, and proliferation. Proc Annu Meet Am Assoc Cancer Res. 37:A2894 1996.
|
